EULAV Asset Management Has $7.10 Million Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

EULAV Asset Management cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 17.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,000 shares of the biotechnology company's stock after selling 23,000 shares during the period. EULAV Asset Management owned 0.06% of BioMarin Pharmaceutical worth $7,099,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of BMRN. Fifth Third Bancorp lifted its stake in shares of BioMarin Pharmaceutical by 13.9% during the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock worth $89,000 after buying an additional 165 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its stake in BioMarin Pharmaceutical by 0.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 21,105 shares of the biotechnology company's stock worth $1,483,000 after acquiring an additional 173 shares during the last quarter. Advisors Asset Management Inc. lifted its position in BioMarin Pharmaceutical by 1.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company's stock worth $805,000 after acquiring an additional 180 shares during the period. TD Private Client Wealth LLC grew its stake in BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 186 shares during the last quarter. Finally, First Hawaiian Bank grew its stake in BioMarin Pharmaceutical by 1.4% during the 4th quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock valued at $966,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BMRN shares. William Blair downgraded BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 30th. Canaccord Genuity Group decreased their price objective on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating for the company in a research note on Wednesday, October 30th. UBS Group increased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Wolfe Research assumed coverage on shares of BioMarin Pharmaceutical in a report on Friday, November 15th. They set an "outperform" rating and a $95.00 target price for the company. Finally, StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $94.20.

BioMarin Pharmaceutical Stock Up 3.6 %

NASDAQ:BMRN traded up $2.31 on Wednesday, reaching $65.86. The stock had a trading volume of 1,187,703 shares, compared to its average volume of 1,526,225. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 12-month low of $60.63 and a 12-month high of $94.85. The company has a 50-day moving average of $64.95 and a 200 day moving average of $71.78. The stock has a market cap of $12.55 billion, a P/E ratio of 39.44, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.